Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

Mansoura University

Status and phase: Enrolling; Phase 4

Conditions: Cirrhosis; HCC - Hepatocellular Carcinoma; Portal Vein Thrombosis

Treatments: Drug: Enoxaparin, warfarrin, or apixaban

Study type: Interventional

Funder types: Other

Identifiers

NCT07132515

MS.23.07.2479

Details and patient eligibility

About

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Portal vein thrombosis, Cirrhosis, With or without HCC, Child A & B

Exclusion criteria

• Platelets<10000, Createnine >1.9, Budd ciarri, Uncontrolled active bleeding

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

100 participants in 3 patient groups

Anticoagulant in cirrhosis with HCC

Experimental group

Description:

HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)

Treatment:

Drug: Enoxaparin, warfarrin, or apixaban

Anticoagulant in Cirrhosis without HCC

Experimental group

Description:

Benign thrombus in cirrhotic patient on anticoagulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)

Treatment:

Drug: Enoxaparin, warfarrin, or apixaban

No anticoagualnt in Cirrhosis with or without HCC

No Intervention group

Description:

cirrhotic patients with thrombosis with or without HCC not on anticoagulant